Cited by 127Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerBioactive Compounds and Antitumor Agents

Antitumor activity of pyrvinium pamoate, 6‐(dimethylamino)‐2‐[2‐(2,5‐dimethyl‐1‐phenyl‐1 H‐pyrrol‐3‐yl)ethenyl]‐1‐methyl‐quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation

Open access
Esumi, Hiroyasu, Lu, Jie, Kurashima, Yukiko, Hanaoka, Tomoyuki·2004·Cancer Science

Abstract

An anthelminthic, pyrvinium pamoate (PP), 6‐(dimethylamino)‐2‐[2‐(2,5‐dimethyl‐1‐phenyl‐1 H‐pyrrol‐3‐yl)ethenyl]‐1‐methyl‐quino‐linium pamoate salt, has been found to be extremely toxic to PANC‐1 cells in glucose‐free medium, but not to be toxic to the same cells cultured in ordinary medium, Dulbecco's modified Eagle's medium (DMEM). It showed the same preferential toxicity for various cancer cell lines during glucose starvation. When 0.1 μg/ml PP was added to the medium, spheroid growth of human colon cancer cell line WiDr was strongly inhibited to a diameter of 750 μm, and this finding is consistent with the concept of anti‐austerity. PP was also found to exert antitumor activity against human pancreatic cancer cell line PANC‐1 in nude mice and SCID mice when it was administered subcutaneously or orally. Regarding the mechanism of PP action, inhibition of Akt phosphoryla‐tion, which has been found to be essential for the austerity mechanism, was observed in vitro and in vivo. These findings indicate that PP may be useful for anticancer therapy and that anti‐austerity therapy could be a novel strategy for anticancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1349-7006.2004.tb03330.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
  2. Weinberg RA. The molecular basis of carcinogenesis: understanding the cell cycle clock. Cytokines Mol Ther 1996; 2: 105-10.
  3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
  4. Folkman J. Looking for a good endothelial address. Cancer Cell 2002; 1: 113-5.
  5. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemo- therapeutic agents: characterization in comparison to their tumor growth in- hibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4: 1331-6.
  6. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H. Diagnosis and follow-up of small hepatocellular carcinoma with selective in- traarterial digital subtraction angiography. Hepatology 1993; 17: 1003-7.
  7. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-8.
  8. Sutherland RM. Tumor hypoxia and gene expression-implications for malig- nant progression and therapy. Acta Oncol 1998; 37: 567-74.
  9. Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micro- milieu of breast cancers: characterization and therapeutic relevance. Int J Oncol 2000; 17: 869-79.
  10. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin On- col 2001; 28: 36-41.
  11. Esumi H, Izuishi K, Kato K, Hashimoto K, Kurashima Y, Kishimoto A, Ogura T, Ozawa T. Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent manner. J Biol Chem 2002; 277: 32791-8.
  12. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for can- cer therapy. Cancer Res 2000; 60: 6201-7.
  13. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M, Esumi H. Critical roles of AMP-activated protein kinase in constitutive toler- ance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002; 21: 6082-90.
  14. Abdallah A, Saif M, Abdel-Fattah F. Pyrvinium pamoate in the treatment of enterobiasis. J Egypt Med Assoc 1965; 48: 396-8.
  15. Prichard RK. Mode of action of the anthelminthic thiabendazole in Haemon- chus contortus. Nature 1970; 228: 684-5.
  16. Sangster NC, Prichard RK. The contribution of a partial tricarboxylic acid cycle to volatile end-products in thiabendazole-resistant and susceptible Tri- chostrongylus colubriformis. Mol Biochem Parasitol 1985; 14: 261-74.
  17. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Lavin MF, Esumi H. Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J Biol Chem 2003; 278: 48-53.
  18. Knighton D, Ausprunk D, Tapper D, Folkman J. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 1977; 35: 347- 56.
  19. Franko AJ, Chapman JD. Binding of 14 C-misonidazole to hypoxic cells in V79 spheroids. Br J Cancer 1982; 45: 694-9.
  20. Smith TC, Kinkel AW, Gryczko CM, Goulet JR. Absorption of pyrvinium pamoate. Clin Pharmacol Ther 1976; 19: 802-6.
  21. Kunimoto S, Lu J, Esumi H, Yamazaki Y, Kinoshita N, Honma Y, Hamada M, Ohsono M, Ishizuka M, Takeuchi T. Kigamicins, novel antitumor antibi- otics: I. taxonomy, isolation, physico-chemical properties and biological ac- tivities. J Antibiot (Tokyo) 2003; 56: 1004-11.
  22. Kunimoto S, Someno T, Yamazaki Y, Lu J, Esumi H, Naganawa H. Kigamicins, novel antitumor antibiotics: II. structure determination. J Anti- biot (Tokyo) 2003; 56: 1012-7.
  23. Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting can- cer cell's tolerance to nutrient starvation. Cancer Sci 2004; 95: 547-52.
  24. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H. ARK5 sup- presses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 2003; 22: 6177-82.
  25. Brugmans JP, Thienpont DC, van Wijngaarden I, Vanparijs OF, Schuermans VL, Lauwers HL. Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects. JAMA 1971; 217: 313-6.
  26. Sheth UK. Mechanisms of anthelmintic action. Prog Drug Res 1975; 19: 147-57.
  27. Anya AO, Umezurike GM. Respiration and carbohydrate energy metabolism of the lung-dwelling parasite Rhabdias bufonis (Nematoda: Rhabdiasoidea). Parasitology 1978; 76: 21-7.
  28. Kita K, Hirawake H, Miyadera H, Amino H, Takeo S. Role of complex II in anaerobic respiration of the parasite mitochondria from Ascaris suum and Plasmodium falciparum. Biochim Biophys Acta 2002; 1553: 123-39.
  29. Weinberg JM, Venkatachalam MA, Roeser NF, Saikumar P, Dong Z, Senter RA, Nissim I. Anaerobic and aerobic pathways for salvage of proximal tu- bules from hypoxia-induced mitochondrial injury. Am J Physiol Renal Phys- iol 2000; 279: F927-43.

Cited by

Sorted by citations

Authors
Esumi, H., Lu, J., Kurashima, Y., & Hanaoka, T.
Affiliations
National Cancer Center Hospital East (JP)
Corresponding author
Esumi, Hiroyasu
Venue
Cancer Science
Publisher
Wiley
Published
2004-08
Volume
95
Issue
8
Pages
685-690
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W1968162861
Cited by
127
References
2
Citations by year
2025: 3 · 2024: 6 · 2023: 1 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 3 · 2015: 12 · 2014: 5 · 2013: 11 · 2012: 10
FWCI
0.56
Type
journal article
Language
en
Open access
Locations
  • Cancer Science (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
pyrvinium pamoate, anthelmintic repurposing, glucose deprivation, pancreatic cancer, colon cancer, PANC-1 cells, WiDr cells, anticancer activity, anticancer drug discovery
MeSH terms
Animals, Cell Division, Colonic Neoplasms, Glucose, Humans, Immunohistochemistry, Mice, Nude, Pancreatic Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Pyrvinium Compounds, Tumor Cells, Cultured, Protein Serine-Threonine Kinases, Cell Culture Techniques, Cell Size, Proto-Oncogene Proteins c-akt, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review